Benign prostatic hyperplasia is a chronic disease, which appears progressively affecting three quarters of men after the age of sixty.Asymptomatic BPH does not require any treatement. whereas “clinical”BPH must be treated, taking into account different criteria such as : The initial assessment of data, patient preferences, potential treatments for the improvement of the symptoms, the expectations in terms of treatment efficiency and the rapidity of its effect, side effects, the quality of life and the progression of the disease. the progress made in the comprehension of BPH’s epidemiology and pathophysiology, has led to multiple changes in its treatment. The advent of new surgical and medical treatments in BHP offer nowadays a wide range of therapeuti options for symptoms of the lower urinary tract, secondary to the disease. (Lower urinary tract symptoms [LUTS/BPH]) Today, thanks a large scale of therapeutic options, new interventional therapies can now be discussed with patients, who should all be informed of these therapeutic alternatives, acceptable and applicable to their clinical state thus the advantages, risks and cost of each modality, so that they can participate actively in the selection of the treatment. A review of the literature has been performed from a selection of articles of the highest level of evidence on the therapeutic management of the Benign prostatic hyperplasia.